Print PDF

Sheppard Mullin Advises Aditx Therapeutics in IPO


Sheppard Mullin advised Aditx Therapeutics, Inc. in connection with its initial public offering.  Aditx’s shares began trading on the Nasdaq Capital Market on June 30, 2020 under the ticker symbol “ADTX.”

Aditx Therapeutics, Inc., a Delaware corporation, is developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. 

The Sheppard Mullin corporate team included New York partner Richard Friedman and associates Alex Yarbrough and Taylor Ashton.

Click here to read Aditx’s press release.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.